In an interview with PharmaShots, Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics share his views on $116M Series B financing and what does this milestone means for the company's pipeline.
Shots:
The Series B financing was led by Wellington Management Company, who was joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment…
